Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin

Abstract

Aim

To determine whether a compliance-enhancing program could increase the level of lipid control in patients treated with rosuvastatin.

Methods and results

A total of 8108 patients (56% men, mean age 59 years; 44% women, mean age 63 years) with low-density lipoprotein cholesterol (LDL-C) ≥ 115 mg/dl if statin-naive or else ≥ 125 mg/dl were randomized to rosuvastatin 10 mg daily either with or without a compliance-enhancing program for 12 months. Patients not achieving the goal after 3 months were uptitrated to rosuvastatin 20 mg daily thereafter. At 3, 6, and 12 months, rosuvastatin plus compliance initiatives were similarly effective to rosuvastatin alone in terms of 1998 European LDL-C goal of less than 115 mg/dl achievement (72 vs. 70%, 71 vs. 69%, 68 vs. 68%) and changes in the lipid profile. Significant differences were observed in the subgroup of statin-naive patients at 3 and 6 months (80 vs. 76% and 78 vs. 73%, P < 0.01). The frequency of adverse events and relevant changes in laboratory data were consistent with the known safety profile of rosuvastatin.

Conclusion

Rosuvastatin 10/20 mg daily enables the majority of patients to achieve LDL-C less than 115 mg/dl within 3 months. The compliance-enhancing program was only effective in statin-naive patients at early time points, but had no overall effect over 12 months. Eur J Cardiovasc Prev Rehabil 16:180-187 © 2009 The European Society of Cardiology

Keywords

atherosclerosis cholesterol compliance lipids rosuvastatin

Get full access to this article

View all access options for this article.

References

1 Murray

Lopez

. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997; 349:1498–1504.

2 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7–22.

Cannon

Braunwald

McCabe

Rader

Rouleau

Belder

Pravastatin or atorvastatin evaluation and infection therapy – thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495–1504.

LaRosa

Grundy

Waters

Shear

Barter

Fruchart

Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425–1435.

Baigent

Keech

Kearney

Blackwell

Buck

Pollicini

Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–1278.

6 Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.

De Backer

Ambrosioni

Borch-Johnsen

Brotons

Cifkova

Dallongeville

Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601–1610.

8 Pearson

Laurora

Chu

Kafonek

. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459–467.

9 EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22:554–572.

10.

10 Marcelino

Feingold

. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100:605–610.

11.

11 Di Martino

Degli Esposti

Ruffo

Bustacchini

Catte

Sturani

Degli Esposti

. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 2005; 61:225–230.

12.

12 Parris

Lawrence

Mohn

Long

. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28:595–599.

13.

13 Jackevicius

Mamdani

. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462–467.

14.

14 Piette

Heisler

Wagner

. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health 2004; 94:1782–1787.

15.

15 Riesen

Darioli

Noll

. Lipid-lowering therapy: strategies for improving compliance. Curr Med Res Opin 2004; 20:165–173.

16.

16 Richter

Anton

Koch

Dennett

. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25:2307–2335.

17.

17 Valdez

Ulrich

. Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. J Manag Care Pharm 2005; 11:499–504.

18.

18 Larsen

Andersen

Kragstrup

Gram

. High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol 2002; 53:375–378.

19.

19 Avorn

Monette

Lacour

Bohn

Monane

Mogun

LeLorier

. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279:1458–1462.

20.

20 Schultz

O'Donnell

McDonough

Sasane

Meyer

. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005; 11:306–312.

21.

21 Andrade

Walker

Gottlieb

Hollenberg

Testa

Saperia

Platt

. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332:1125–1131.

22.

22 Strandberg

Lehto

Pyorala

Kesaniemi

Oksa

. Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. Eur Heart J 1997; 18:1725–1727.

23.

Willich

Muller-Nordhorn

Sonntag

Voller

Meyer-Sabellek

Wegscheider

Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the open label primary care study: rosuvastatin based compliance initiatives to achievements of LDL goals (ORBITAL) study. Am Heart J 2004; 148:1060–1067.

24.

24 Wood

De Backer

Faergeman

Graham

Mancia

Pyörälä

. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Recommendations of the Second joint task force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434–1503.

25.

25 Haynes

McDonald

Grag

Montague

. Interventions for helping patients to follow prescriptions for medications (Cochrane Review). In: Cochrane Library, Issue 2. Oxford: Update Software, 2003.

26.

Jones

Davidson

Stein

Bays

McKenney

Miller

Stellar Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92:152–160.

27.

Schuster

Barter

Stender

Cheung

Bonnet

Morrell

Mercury I study group. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J 2004; 147:705–712.

28.

28 Fonseca

Ruiz

Cardona-Munoz

Silva

Fuenmayor

Marotti

. Discovery Penta investigators. The Discovery Penta study: a direct statin comparison of LDL-C Value – an evaluation of rosuvastatin therapy compared with atorvastatin. Curr Med Res Opin 2005; 21:1307–1315.

29.

29 Truppo

Keller

Reusch

Pandya

Bendich

. The effect of a comprehensive, mail-based motivational program for patients receiving lipid-lowering therapy Manag Care Interface 2003; 16:35–40, 62.

30.

Benner

Tierce

Ballantyne

Prasad

Bullano

Willey

Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy

Pharmacoeconomics 2004; 22 (Suppl 3):13–23.

31.

Lichtman

Amatruda

Yaari

Cheng

Smith

Mattera

Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. Am Heart J 2004; 147:522–528.

32.

Brewer

Jr.

Benefit-risk assessment of rosuvastatin 10–40 milligrams

Am J Cardiol 2003; 92 (Suppl):23K–29K.

33.

33 Newman

Palmer

Silbershatz

Szarek

. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003; 92:670–676.

34.

34 Shepherd

Hunninghake

Stein

Kastelein

Harris

Pears

Hutchinson

. Safety of rosuvastatin. Am J Cardiol 2004; 94:882–888.

35.

35 Strandberg

Feely

Sigurdsson

, Discovery study group Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a Discovery study. Clin Ther 2004; 26:1821–1833.

36.

36 Vidt

Cressman

Harris

Pears

Hutchinson

. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102:52–60.